Skip to main content

Advertisement

SpringerLink
Log in

Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

Frizzled homolog 10 (FZD10) is expressed at high levels on the cell surface of almost all synovial sarcoma tissues, but is absent in most normal organs. In a previous study, yttrium-90 (90Y)-labeled anti-FZD10 antibody (MAb 92-13) showed considerable therapeutic efficacy in synovial sarcoma cell-bearing mice. The purpose of the present study was to elucidate the factors associated with this therapeutic efficacy of 90Y-MAb 92-13.

Methods

FZD10 expression levels of SYO-1 (FZD10-overexpressing synovial sarcoma cell line) and DLD-1/FZD10 (FZD10-transfected DLD-1 cell) were determined by the cell binding assay, and their radiosensitivity was evaluated by incubation with 90Y-MAb 92-13 in vitro. Biodistribution study of indium-111 (111In)-MAb 92-13 was performed in SYO-1 and DLD-1/FZD10 tumor-bearing mice. For therapeutic studies, SYO-1 and DLD-1/FZD10 tumor-bearing mice were treated with 90Y-MAb 92-13 (100, 150, and 200 μCi), after which the change in tumor volume was measured. Immunohistochemical staining was performed on the excised tumor.

Results

Expression level of FZD10 on DLD-1/FZD10 was much greater than that on SYO-1. The accumulation of 111In-MAb 92-13 was much higher in DLD-1/FZD10 tumor-bearing mice than in SYO-1 tumor-bearing mice (49.0 ± 4.2 and 22.0 ± 4.5% ID/g, respectively, at 48 h after administration). In SYO-1 tumor, substantial tumor size reduction was observed in all mice treated with 90Y-MAb 92-13 (tumor volume decreased to less than 0.1 cm3 at 11 days after treatment) and tumor regrowth was not observed in most of them. In contrast, only slow progression was observed in DLD-1/FZD10 tumor. When incubated with 90Y-MAb 92-13, high radioactivity was needed to damage DLD-1/FZD10. Immunohistochemical study indicated apoptosis of SYO-1 tumor.

Conclusions

The therapeutic efficacy of RIT seems to largely depend on the tumor radiosensitivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007;109:1804–10.

    Article  PubMed  CAS  Google Scholar 

  2. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas. J Clin Oncol. 2005;23:7565–73.

    Article  PubMed  CAS  Google Scholar 

  3. Verhaar-Langereis MJ, Zonnenberg BA, de Klerk JM, Blijham GH. Radioimmunodiagnosis and therapy. Cancer Treat Rev. 2000;26:3–10.

    Article  PubMed  CAS  Google Scholar 

  4. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother. 2003;52:281–96.

    PubMed  CAS  Google Scholar 

  5. Jhanwar YS, Divgi C. Current status of therapy of solid tumors. J Nucl Med. 2005;46:141S–50S.

    PubMed  Google Scholar 

  6. Koppe MJ, Postema EJ, Aarts F, Oyen WJ, Bleichrodt RP, Boerman OC. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev. 2005;24:539–67.

    Article  PubMed  CAS  Google Scholar 

  7. Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol. 2007;34:757–78.

    Article  PubMed  CAS  Google Scholar 

  8. Koike J, Takagi A, Miwa T, Hirai M, Terada M, Katoh M. Molecular cloning of Frizzled-10, a novel member of the Frizzled gene family. Biochem Biophys Res Commun. 1999;262:39–43.

    Article  PubMed  CAS  Google Scholar 

  9. Nagayama S, Katagiri T, Tsunoda T, Hosaka T, Nakashima Y, Araki N, et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA Microarray. Cancer Res. 2002;62:5859–66.

    PubMed  CAS  Google Scholar 

  10. Nagayama S, Fukukawa C, Katagiri T, Okamoto T, Aoyama T, Oyaizu N, et al. Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas. Oncogene 2005;24:6201–12.

    Article  PubMed  CAS  Google Scholar 

  11. Fukukawa C, Hanaoka H, Nagayama S, Tsunoda T, Toguchida J, Endo K, et al. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci. 2008;99:432–40.

    Article  PubMed  CAS  Google Scholar 

  12. Tsai SW, Sun Y, Williams LE, Raubitschek AA, Wu AM, Shively JE. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Bioconjug Chem. 2000;11:327–34.

    Article  PubMed  CAS  Google Scholar 

  13. Berger MA, Masters GR, Singleton J, Scully MS, Grimm LG, Soltis DA, et al. Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine model of human ovarian cancer. Cancer Biother Radiopharm. 2005;20:589–602.

    Article  PubMed  CAS  Google Scholar 

  14. Zhao XY, Schneider D, Biroc SL, Parry R, Alicke B, Toy P, et al. Targeting tomoregulin for radioimmunotherapy of prostate cancer. Cancer Res. 2005;65:2846–53.

    Article  PubMed  CAS  Google Scholar 

  15. Kelly MP, Lee FT, Smyth FE, Brechbiel MW, Scott AM. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. J Nucl Med. 2006;47:716–25.

    PubMed  CAS  Google Scholar 

  16. Arano Y, Fujioka Y, Akizawa H, Ono M, Uehara T, Wakisaka K, et al. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Res. 1999;59:128–34.

    PubMed  CAS  Google Scholar 

  17. Scatchard G. The attraction of proteins for small molecules and ions. Ann NY Acad Sci. 1949;51:660–72.

    Article  CAS  Google Scholar 

  18. Ng B, Kramer E, Liebes L, Wasserheit C, Hochster H, Blank E, et al. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts. Cancer Res. 2001;61:2996–3001.

    PubMed  CAS  Google Scholar 

  19. Hnatowich DJ, Virzi F, Doherty PW. DTPA-coupled antibodies labeled with yttrium-90. J Nucl Med. 1985;26:503–9.

    PubMed  CAS  Google Scholar 

  20. Roselli M, Schlom J, Gansow OA, Raubitschek A, Mirzadeh S, Brechbiel MW, et al. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med. 1989;30:672–82.

    PubMed  CAS  Google Scholar 

  21. Saga T, Sakahara H, Nakamoto Y, Sato N, Ishimori T, Mamede M, et al. Enhancement of the therapeutic outcome of radio-immunotherapy by combination with whole-body mild hyperthermia. Eur J Cancer. 2001;37:1429–34.

    Article  PubMed  CAS  Google Scholar 

  22. Rupnow BA, Murtha AD, Alarcon RM, Giaccia AJ, Knox SJ. Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res. 1998;58:1779–84.

    PubMed  CAS  Google Scholar 

  23. Macklis RM, Beresford BA, Humm JL. Radiobiologic studies of low-dose-rate 90Y-lymphoma therapy. Cancer 1994;73:966–73.

    Article  PubMed  CAS  Google Scholar 

  24. Friesen C, Lubatschofski A, Kotzerke J, Buchmann I, Reske SN, Debatin KM. Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells. Eur J Nucl Med Mol Imaging. 2003;30:1251–61.

    Article  PubMed  CAS  Google Scholar 

  25. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123–9.

    PubMed  CAS  Google Scholar 

  26. Hartman T, Lundqvist H, Westlin JE, Carlsson J. Radiation doses to the cell nucleus in single cells and cells in micrometastases in targeted therapy with 131I labeled ligands or antibodies. Int J Radiat Oncol Biol Phys. 2000;46:1025–36.

    PubMed  CAS  Google Scholar 

  27. Nagayama S, Yamada E, Kohno Y, Aoyama T, Fukukawa C, Kubo H, et al. Inverse correlation of the up-regulation of FZD10 expression and the activation of beta-catenin in synchronous colorectal tumors. Cancer Sci. 2009;100:405–12.

    Article  PubMed  CAS  Google Scholar 

  28. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003;22:2192–205.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by Grant-in-Aid for Young Scientists (B) (19790855) and Grant-in-Aid for Scientific Research on Priority Areas (17016008).

Author information

Authors and Affiliations

  1. Department of Bioimaging Information Analysis, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, 371-8511, Japan

    Hirofumi Hanaoka & Yasuhiko Iida

  2. Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan

    Toyomasa Katagiri, Chikako Fukukawa & Yusuke Nakamura

  3. Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan

    Hiroki Yoshioka, Shinji Yamamoto, Tetsuya Higuchi, Noboru Oriuchi, Bishnuhari Paudyal, Pramila Paudyal & Keigo Endo

Authors
  1. Hirofumi Hanaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toyomasa Katagiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chikako Fukukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroki Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shinji Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasuhiko Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tetsuya Higuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Noboru Oriuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bishnuhari Paudyal
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pramila Paudyal
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yusuke Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Keigo Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hirofumi Hanaoka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanaoka, H., Katagiri, T., Fukukawa, C. et al. Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity. Ann Nucl Med 23, 479–485 (2009). https://doi.org/10.1007/s12149-009-0265-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-009-0265-1

Keywords

Search

Navigation